RECURSION PHARMACEUTICALS, INC. (RXRX) Operating income 2019–2025
RECURSION PHARMACEUTICALS, INC. (RXRX) annual operating income history from SEC filings — each fiscal year as reported.
-$648.1MFY2025 · since FY2019: -$62.4M → -$648.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$648.1M | -35.3% |
| FY2024 | -$479.0M | -36.8% |
| FY2023 | -$350.1M | -42.5% |
| FY2022 | -$245.7M | -34.4% |
| FY2021 | -$182.8M | -116.0% |
| FY2020 | -$84.6M | -35.5% |
| FY2019 | -$62.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice